Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) (Mel66)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04364230
Recruitment Status : Recruiting
First Posted : April 28, 2020
Last Update Posted : May 4, 2022
Sponsor:
Collaborator:
Celldex Therapeutics
Information provided by (Responsible Party):
Craig L Slingluff, Jr, University of Virginia

Brief Summary:
This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants. The adjuvants that will be used in this trial are a CD40 antibody (CDX-1140) and a toll-like receptor (TLR) 3 agonist (Poly-ICLC). The study will also investigate the effects of the vaccine and the adjuvants on the immune response. The investigators will monitor these effects by performing tests in the laboratory on participants' blood and skin tissue.

Condition or disease Intervention/treatment Phase
Melanoma Ocular Melanoma Uveal Melanoma Drug: 6MHP Drug: NeoAg-mBRAF Drug: PolyICLC Drug: CDX-1140 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma
Actual Study Start Date : September 28, 2020
Estimated Primary Completion Date : September 2024
Estimated Study Completion Date : May 2025


Arm Intervention/treatment
Experimental: All Participants
6MHP (200mcg of each peptide) and 300mcg of NeoAg-mBRAF will be co-administered locally with 0.9mg of polyICLC and CDX-1140. There will be a dose escalation of CDX-1140 (50mcg, 200mcg, 800mcg, 3.0mg). A vaccine containing all of these components will be given on days 1, 22, 43, and 64. The vaccine will be given subcutaneously/intradermally.
Drug: 6MHP
6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
Other Name: 6 melanoma helper peptide vaccine

Drug: NeoAg-mBRAF
BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
Other Name: BRAF 585-614 (V600E)

Drug: PolyICLC
polyICLC, local adjuvant

Drug: CDX-1140
CDX-1140, local adjuvant




Primary Outcome Measures :
  1. Safety of CDX-1140 + melanoma peptide vaccine (6MHP and NeoAg-mBRAF) + PolyICLC [ Time Frame: 30 days after receiving the last dose of study drug ]
    Number of participants with dose-limiting toxicities based on CTCAE v5.0

  2. Immunogenicity: Estimate immune response rate to a melanoma vaccine combined with CDX-1140 [ Time Frame: Day 85 and/or Day 176 ]
    Number of participants with durable or persistent C4+ Th1 responses to the melanoma vaccine at either day 85 or day 176, or both


Secondary Outcome Measures :
  1. Immunogenicity: Impact of vaccine containing peptides plus CDX-1140 and polyICLC on regulatory T cells [ Time Frame: Day 50 ]
    Number of FoxP3+ CD4+ T cells per mm^2 in vaccine site biopsies

  2. Immunogenicity: Impact of addition of CDX-1140 to melanoma vaccine on circulating regulatory T cells [ Time Frame: Through Day 85 ]
    Number of participants with circulating Tregs (CD4+ FoxP3+) as a proportion of circulating CD4 T cells

  3. Immunogenicity: Impact of addition of CDX-1140 to melanoma vaccine on induction of CD4+ Th1 responses to vaccine antigens [ Time Frame: Through Day 176 ]
    Number of participants with CD4+ T cell response; maximum increase after vaccination at any time point.

  4. Immunogenicity: Impact of addition of CDX-1140 to melanoma vaccine on CD4+ Th1 memory response to vaccine antigens [ Time Frame: Day 176 ]
    Number of participants with CD4+ T cell response to the melanoma peptides



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  1. a. For individuals with primary cutaneous, mucosal, or unknown melanoma, an individual must have stage IB ulcerated, II, III, or IV melanoma at original diagnosis or at restaging after recurrence, and be rendered clinically free of disease by surgery, other therapy, or spontaneous remission within 6 months prior to registration.

    b. For patients with stage II, III, or IV uveal melanoma, patients must be rendered clinically free of disease by surgery, other therapy, or spontaneous remission within 6 months prior to registration.

  2. An individual with small radiologic or clinical findings of an indeterminate nature may still be eligible
  3. An individual may have had cutaneous, uveal, mucosal primary melanoma, or an unknown primary melanoma.
  4. Biopsies of nevi are optional. Participants with at least 4-10 evaluable nevi at least 4 mm in diameter that are located on truncal or non-acral extremity sites and are accessible for biopsy and observation will be asked to participate in the optional nevi biopsies
  5. Diagnosis of melanoma must be confirmed by cytological or histological examination except that patients with clinically localized primary uveal melanoma will not require pathologic review.
  6. Individuals will be required to have radiological studies to rule out radiologically evident melanoma metastasis.
  7. Individuals who have had brain metastases will be eligible if all of the following are true:

    • Each brain metastasis must have been completely removed by surgery or each unresected brain metastasis must have been treated with stereotactic radiosurgery.
    • No brain metastasis is > 2 cm in diameter at the time of registration.
    • Any neurologic symptoms attributable to brain metastases have returned to baseline.
    • There is no evidence of new or enlarging brain metastases.
  8. The most recent surgical resections or gamma-knife therapy for malignant melanoma must have been completed ≥ 1 week and ≤ 6 months prior to registration.
  9. ECOG performance status of 0 or 1 (Section 13.3).
  10. Ability and willingness to give informed consent.
  11. Adequate organ function as determined by laboratory parameters.
  12. Male or female, age 18 years or older at registration.
  13. Individuals must have at least one intact (undissected) axillary and/or inguinal lymph node basin.
  14. For females and males of reproductive potential: agreement to use adequate contraception during study participation and for an additional 3 months after receiving the last dose of study drug.

Main Exclusion Criteria:

  1. Individuals who have received the following medications or treatments at any time within 4 weeks of registration:

    • Chemotherapy
    • Interferon (e.g. Intron-A®)
    • Radiation therapy (Stereotactic radiotherapy, such as gamma knife, can be used ≥ 1 week and ≤ 6 months prior to registration)
    • Allergy desensitization injections
    • High doses of systemic corticosteroids, with some qualifications and exceptions
    • Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)
    • Interleukins (e.g. Proleukin®)
    • Any investigational medication
    • Targeted therapies specific for mutated BRAF or for MEK
  2. Individuals who are currently receiving nitrosoureas or who have received this therapy within 6 weeks of registration.
  3. Individuals who are currently receiving a checkpoint molecule blockade therapy, or who have received this therapy within 12 weeks of registration.
  4. Individuals with known or suspected allergies to any component of the vaccine.
  5. Individuals who have received prior melanoma vaccinations with 6MHP plus the mutated BRAF peptide. However, participants who have received prior vaccinations will be eligible to enroll 12 weeks following their last vaccination if they have recurred during or after administration of the vaccine, and if their vaccines did not include all of the synthetic peptides included in this protocol.
  6. Individuals who have previously received CDX-1140 or another CD40 agonistic antibody.
  7. Pregnancy. Female individuals of childbearing potential must have a negative pregnancy test (urinary or serum beta-HCG) obtained within 2 weeks prior to registration.
  8. HIV positivity or evidence of active Hepatitis C virus (testing to be done within 6 months of study entry).
  9. Female individuals must not be breastfeeding.
  10. Individuals in whom there is a medical contraindication or potential problem in complying with the requirements of the protocol in the opinion of the investigator.
  11. Individuals classified according to the New York Heart Association classification as having Class III or IV heart disease (Section 13.4).
  12. Individuals must not have had prior autoimmune disorders requiring systemic cytotoxic or immunosuppressive therapy, or autoimmune disorders with visceral involvement. Participants with an active autoimmune disorder requiring these therapies are also excluded. Some autoimmune disorders will not be exclusionary:

    • The presence of laboratory evidence of autoimmune disease (e.g. positive ANA titer) without symptoms
    • Clinical evidence of vitiligo
    • Other forms of depigmenting illness
    • Mild arthritis requiring non-steroidal anti-inflammatory drugs (NSAID) medications
    • Resolved childhood asthma/atopy
    • Endocrinopathies on stable hormone replacement therapy
  13. Individuals with known addiction to alcohol or drugs who are actively taking those agents, or participants with recent (within 1 year) or ongoing illicit IV drug use.
  14. Individuals with current pneumonitis. Individuals must not have had pneumonitis within 30 days of registration. Patients who have had complete resolution of prior pneumonitis will be eligible.
  15. Individuals who have received a live vaccine within 30 days of registration.
  16. Body weight < 110 pounds (50 kg) at registration

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04364230


Contacts
Layout table for location contacts
Contact: Adela Mahmutovic, BS 1-434-982-6714 am6bd@hscmail.mcc.virginia.edu

Locations
Layout table for location information
United States, Ohio
Cleveland Clinic Taussig Cancer Center Recruiting
Cleveland, Ohio, United States, 44195
Contact: Katie Caputo    216-444-2558    CAPUTOK2@ccf.org   
Contact: Laura Van Varik       vanvarl@ccf.org   
Principal Investigator: Brian Gastman, MD         
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Adela Mahmutovic, BS    434-982-6714    am6bd@hscmail.mcc.virginia.edu   
Sponsors and Collaborators
Craig L Slingluff, Jr
Celldex Therapeutics
Investigators
Layout table for investigator information
Principal Investigator: Craig Slingluff University of Virginia
Layout table for additonal information
Responsible Party: Craig L Slingluff, Jr, Professor of Surgery; Director, Human Immune Therapy Center, University of Virginia
ClinicalTrials.gov Identifier: NCT04364230    
Other Study ID Numbers: HSR200006
First Posted: April 28, 2020    Key Record Dates
Last Update Posted: May 4, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Craig L Slingluff, Jr, University of Virginia:
peptide
vaccine
6MHP
adjuvant
polyICLC
CDX-1140
NeoAg-mBRAF
CD40
TLR
nevi
nevus
BRAF585-614-V600E
Ocular Melanoma
Uveal Melanoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Poly ICLC
Immunologic Factors
Physiological Effects of Drugs
Interferon Inducers